UY29499A1 - Vacunas multivalentes del papilomavirus humano (vph) - Google Patents

Vacunas multivalentes del papilomavirus humano (vph)

Info

Publication number
UY29499A1
UY29499A1 UY29499A UY29499A UY29499A1 UY 29499 A1 UY29499 A1 UY 29499A1 UY 29499 A UY29499 A UY 29499A UY 29499 A UY29499 A UY 29499A UY 29499 A1 UY29499 A1 UY 29499A1
Authority
UY
Uruguay
Prior art keywords
hpv
multivalent vaccines
human papilomavirus
vaccines
human
Prior art date
Application number
UY29499A
Other languages
English (en)
Inventor
Gary Dubin
Bruce Innis
Moncef Mohammed Slaoui
Martine Anne Ceci Wettendorffb
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/114,301 external-priority patent/US20050287161A1/en
Priority claimed from PCT/EP2005/006461 external-priority patent/WO2005123125A1/en
Priority claimed from US11/367,601 external-priority patent/US7858098B2/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of UY29499A1 publication Critical patent/UY29499A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a procedimientos y vacunas para tratar infecciones causadas por los papilomavirus humanos. Se ha determinado que la inmunización con partículas semejantes al virus VPH-16 y VPH-18 proporciona protección cruzada contra otros tipos de VPH.
UY29499A 2005-04-26 2006-04-26 Vacunas multivalentes del papilomavirus humano (vph) UY29499A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/114,301 US20050287161A1 (en) 2002-12-20 2005-04-26 Vaccine
PCT/EP2005/006461 WO2005123125A1 (en) 2004-06-16 2005-06-14 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
US11/367,601 US7858098B2 (en) 2002-12-20 2005-12-16 Vaccine

Publications (1)

Publication Number Publication Date
UY29499A1 true UY29499A1 (es) 2006-11-30

Family

ID=37199195

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29499A UY29499A1 (es) 2005-04-26 2006-04-26 Vacunas multivalentes del papilomavirus humano (vph)

Country Status (12)

Country Link
EP (1) EP1879614A2 (es)
JP (1) JP2008539182A (es)
KR (1) KR20080005583A (es)
AR (1) AR053715A1 (es)
AU (1) AU2006239471A1 (es)
CA (1) CA2606206A1 (es)
EA (1) EA013325B1 (es)
MX (1) MX2007013475A (es)
NO (1) NO20075185L (es)
SG (1) SG159529A1 (es)
UY (1) UY29499A1 (es)
WO (1) WO2006114273A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102215861B (zh) * 2009-06-19 2014-10-08 艾金株式会社 宫颈癌疫苗

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
EP1572233B1 (en) * 2002-12-20 2011-03-30 GlaxoSmithKline Biologicals s.a. Use of HPV16 and HPV18 as vaccine against one or more of oncogenic HPV type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
MXPA06014515A (es) * 2004-06-16 2007-03-23 Glaxosmithkline Biolog Sa Vacuna contra vph16 y vph18 y al menos otro tipo de vph seleccionado de vph 31, 45 o 52.

Also Published As

Publication number Publication date
AR053715A1 (es) 2007-05-16
EP1879614A2 (en) 2008-01-23
KR20080005583A (ko) 2008-01-14
CA2606206A1 (en) 2006-11-02
SG159529A1 (en) 2010-03-30
EA200702077A1 (ru) 2008-04-28
EA013325B1 (ru) 2010-04-30
WO2006114273A3 (en) 2007-03-15
NO20075185L (no) 2008-01-25
MX2007013475A (es) 2008-04-02
AU2006239471A1 (en) 2006-11-02
WO2006114273A2 (en) 2006-11-02
JP2008539182A (ja) 2008-11-13

Similar Documents

Publication Publication Date Title
ECSP055869A (es) Vacuna hpv-16 y -18 l1 vlp
CR20150337A (es) Derivados de pirimidinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral
GT201300093A (es) Compuestos antivirales
CL2011001993A1 (es) Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio; metodo de produccion; y su uso para prevenir, mejorar o tratar una enfermedad productiva por el virus del dengue en un sujeto.
ECSP045300A (es) Antígenos virales
CL2012002489A1 (es) Compuestos derivados de sililo nafto-imidazol; composición farmacéutica; y su uso para prevenir o tratar una infección por el virus de la hepatitis c.
ECSP11010937A (es) Compuestos antivirales
WO2007121894A3 (en) Hpv-18-based papillomavirus vaccine
CL2008001294A1 (es) Metodo para la purificacion de un virus o antigeno de un virus mediante gradientes de sacarosa en una ultracentrifuga continua.
CL2007000361A1 (es) Combinacion que comprende un inhibidor de la arn polimerasa del virus de la hepatitis c (vhc) y un inhibidor de la proteasa del vhc; composicion farmaceutica que la comprende; y uso de la combinacion para tratar trastornos asociados con vhc.
WO2011079073A3 (en) Herpes simplex virus vaccines
BR112018011310A2 (pt) mutante da proteína l1 do papilomavírus humano tipo 58
AR105541A1 (es) ANTICUERPOS MONOCLONALES ESPECÍFICOS PARA EL ANTÍGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, ÚTILES PARA LA DETECCIÓN Y EL DIAGNÓSTICO DE LA INFECCIÓN CAUSADA POR VRSh
WO2019099723A3 (en) Materials and methods relating to immunogenic epitopes from human papillomavirus
BR112013017489A2 (pt) materiais e métodos para genotipagem e quantificação de um papiloma vírus humano de alto risco
MX2010005701A (es) Metodo para producir cepa viral vacunal de un virus de la familia reoviridae.
BRPI0810951B8 (pt) proteína l1 do hpv6, polinucleotídeo, vetor, célula, partícula semelhante ao vírus (vlp) hpv6, método para produzir a proteína hpv6 l1 truncada, vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína hpv6 l1 truncada, método para prevenção de condiloma acuminado ou infecções por hpv, método para obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv
ATE549031T1 (de) Impfstoffzusammensetzung zur prävention von cmv- infektionen
EA201400235A1 (ru) Вакцины против гриппа на основе н5
PE20230349A1 (es) Vacunas para la papilomatosis respiratoria recurrente y metodos para usar estas
UY29499A1 (es) Vacunas multivalentes del papilomavirus humano (vph)
BR112017015340A2 (pt) uso de taurina na prevenção e/ou tratamento de doenças induzidas por vírus do gênero coronavírus e/ou gênero rotavírus
CL2013001219A1 (es) Metodo para producir virus monoglucosilado de influenza; virus monoglucosilado del antígeno de influenza ha (virus completo o recombinante); uso del virus para preparar vacuna.
AR041515A1 (es) Vacuna a dna contra el virus de papiloma humano
CR11585A (es) Vacunas para la malaria

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20180405